Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)EBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt issuancesShort-Term Debt repayments
Ratios

Cryo Cell International (CCEL) Shares Outstanding (2016 - 2026)

Cryo Cell International's Shares Outstanding history spans 17 years, with the latest figure at $14.9 million for Q1 2026.

  • Quarterly results put Shares Outstanding at $14.9 million for Q1 2026, changed 0.19% from a year ago — trailing twelve months through Feb 2026 was $14.9 million (changed 0.19% YoY), and the annual figure for FY2025 was $14.9 million, changed 0.19%.
  • Shares Outstanding for Q1 2026 was $14.9 million at Cryo Cell International, roughly flat from $14.9 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $14.9 million in Q3 2025 to a low of $14.7 million in Q1 2022.
  • The 5-year median for Shares Outstanding is $14.8 million (2023), against an average of $14.8 million.
  • The sharpest move saw Shares Outstanding grew 7.44% in 2022, then rose 0.0% in 2024.
  • Year by year, Shares Outstanding stood at $14.8 million in 2022, then rose by 0.01% to $14.8 million in 2023, then grew by 0.0% to $14.8 million in 2024, then increased by 0.19% to $14.9 million in 2025, then changed by 0.0% to $14.9 million in 2026.
  • According to Business Quant data, Shares Outstanding over the past three periods came in at $14.9 million, $14.9 million, and $14.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.